IDYA

IDEAYA Biosciences, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$31.49

Price (1 Year)

$40.11 $28.19

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %0 / %30
Non-compliant assets / Total market cap %43.4 / %30
Non-compliant revenue / Total income %100 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.

Website

Analysis (Turkish): IDYA Hissesi Caiz mi, Helal mi? IDEAYA Biosciences, Inc. Katılım Analizi